Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Shukla Website

Suneet Shukla, Ph.D.

Selected Publications
1)  Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, Dahut WL, Figg WD.
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
BJU Int. 2008. [Journal]
2)  Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, Ambudkar SV.
Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in Mice.
Pharm. Res. 2008. [Journal]
3)  Shukla S, Wu CP, Ambudkar SV.
Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.
Expert opinion on drug metabolism & toxicology. 4: 205-23, 2008. [Journal]
4)  Shukla S, Sauna ZE, Ambudkar SV.
Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.
Leukemia. 22: 445-7, 2008. [Journal]
5)  Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW, Ambudkar SV, Chen ZS.
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Biochem. Pharmacol. 2008. [Journal]
6)  Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE.
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Biochem. Pharmacol. 75: 1302-12, 2008. [Journal]
7)  Shukla S, Robey RW, Bates SE, Ambudkar SV.
Sunitinib (Sutent(R), SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2.
Drug Metab. Dispos. 2008. [Journal]
8)  Calcagno AM, Kim IW, Wu CP, Shukla S, Ambudkar SV.
ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions.
Current drug delivery. 4: 324-33, 2007. [Journal]
9)  Pawarode A, Shukla S, Minderman H, Fricke SM, Pinder EM, O'Loughlin KL, Ambudkar SV, Baer MR.
Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins.
Cancer Chemother. Pharmacol. 60: 179-88, 2007. [Journal]
10)  Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR, Fu LW, Ambudkar SV, Chen ZS.
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Cancer Res. 67: 11012-20, 2007. [Journal]
11)  Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, Ambudkar SV.
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
Mol. Cancer Ther. 6: 3287-96, 2007. [Journal]
12)  Paterson JK, Shukla S, Black CM, Tachiwada T, Garfield S, Wincovitch S, Ernst DN, Agadir A, Li X, Ambudkar SV, Szakacs G, Akiyama S, Gottesman MM.
Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane.
Biochemistry. 46: 9443-52, 2007. [Journal]
13)  Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U, Neubauer A.
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
Leukemia. 21: 1267-75, 2007. [Journal]
14)  Robey RW, Shukla S, Steadman K, Obrzut T, Finley EM, Ambudkar SV, Bates SE.
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure.
Mol. Cancer Ther. 6: 1877-85, 2007. [Journal]
15)  Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV.
Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Mol. Cell. Biochem. 296: 85-95, 2007. [Journal]
16)  Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, Dean M, McMahon JB.
New inhibitors of ABCG2 identified by high-throughput screening.
Mol. Cancer Ther. 6: 3271-8, 2007. [Journal]
17)  Shukla S, Wu CP, Nandigama K, Ambudkar SV.
The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2.
Mol. Cancer Ther. 6: 3279-86, 2007. [Journal]
18)  Rai V, Gaur M, Shukla S, Shukla S, Ambudkar SV, Komath SS, Prasad R.
Conserved Asp327 of walker B motif in the N-terminal nucleotide binding domain (NBD-1) of Cdr1p of Candida albicans has acquired a new role in ATP hydrolysis.
Biochemistry. 45: 14726-39, 2006. [Journal]
19)  Chearwae W, Shukla S, Limtrakul P, Ambudkar SV.
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Mol. Cancer Ther. 5: 1995-2006, 2006. [Journal]
20)  Shukla S, Robey RW, Bates SE, Ambudkar SV.
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.
Biochemistry. 45: 8940-51, 2006. [Journal]
21)  Saini P, Prasad T, Gaur NA, Shukla S, Jha S, Komath SS, Khan LA, Haq QM, Prasad R.
Alanine scanning of transmembrane helix 11 of Cdr1p ABC antifungal efflux pump of Candida albicans: identification of amino acid residues critical for drug efflux.
J. Antimicrob. Chemother. 56: 77-86, 2005. [Journal]
22)  Sauna ZE, Shukla S, Ambudkar SV.
Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections.
Mol Biosyst. 1: 127-34, 2005. [Journal]
23)  Shukla S, Sauna ZE, Prasad R, Ambudkar SV.
Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans.
Biochem. Biophys. Res. Commun. 322: 520-5, 2004. [Journal]
24)  Shukla S, Ambudkar SV, Prasad R.
Substitution of threonine-1351 in the multidrug transporter Cdr1p of Candida albicans results in hypersusceptibility to antifungal agents and threonine-1351 is essential for synergic effects of calcineurin inhibitor FK520.
J. Antimicrob. Chemother. 54: 38-45, 2004. [Journal]
25)  Shukla S, Saini P, Jha S, Ambudkar SV, Prasad R.
Functional characterization of Candida albicans ABC transporter Cdr1p.
Eukaryotic Cell. 2: 1361-75, 2003. [Journal]
26)  Jha S, Karnani N, Dhar SK, Mukhopadhayay K, Shukla S, Saini P, Mukhopadhayay G, Prasad R.
Purification and characterization of the N-terminal nucleotide binding domain of an ABC drug transporter of Candida albicans: uncommon cysteine 193 of Walker A is critical for ATP hydrolysis.
Biochemistry. 42: 10822-32, 2003. [Journal]
27)  Agrawal A, Shukla S, Kale RK.
Role of Ca2+ in radiation-induced damage in murine splenocytes.
Int. J. Radiat. Biol. 79: 733-46, 2003. [Journal]
28)  Henrich C, Bokesch H, Bates S, Robey R, Shukla S, Ambudkar S, Dean M, J M, inventor; DHHS, assignee.
Method of inhibiting ABCG2 and related treatments methods.
Patent Pending, Filed in 2008. Application No. 61/018,758. Pending [Patent]
29)  Henrich C, Bokesch H, Bates S, Robey R, Shukla S, Ambudkar S, Dean M, J M, inventor; DHHS, assignee.
Method of inhibiting ABCG2 and related treatments.
Patent Pending, Filed in 2007. Application No. 60/986,155. Pending [Patent]

This page was last updated on 12/10/2008.